source
- Zura Bio’s Phase 2 trial of tibulizumab fails, shares plungeZura Bio announced that its experimental drug tibulizumab did not meet efficacy endpoints in a Phase 2 study of a painful skin disorder. The company said that both dose levels performed no better t…
- Gene therapy sponsors urged to address six GMP manufacturing considerations earlySK pharmteco’s chief technical officer Tatiana Nanda explained that gene therapy sponsors need to think about manufacturing issues well before reaching GMP production. She told BioSpace that early…